Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Purpose: To prospectively compare the assessment of metabolic response to yttrium 90 ( 90 Y)–ibritumomab tiuxetan radioimmunotherapy (RIT) by using fl uorine 18 ( 18 F) fl uorodeoxyglucose (FDG) combined positron emission tomographic– computed tomographic (PET/CT) imaging at 2 and 6 months to determine the most appropriate time to detect therapeutic response in refractory non–Hodgkin lymphoma (NHL) patients treated with RIT. Materials and Methods: The ethical committee of the university approved the protocol and all patients signed informed consent. Twentythree consecutive patients (10 women, 13 men; mean age, 51.8 years 6 7.3 [standard deviation ]) treated by using RIT for relapsed or refractory follicular NHL were enrolled. For all patients, 18 F FDG PET/CT scanning was performed at baseline and at 2 and 6 months after RIT. Response was assessed by using the International Workshop Criteria (IWC) and revised criteria (IWC + PET) as well as the criteria of the European Organization for Research and Treatment of Cancer. One-way analysis of variance for repeated measures, receiver operator curve analysis, and Kaplan-Meier curves were used for statistical analysis. Results: PET/CT performed at 2 months revealed complete ( n = 12) or partial ( n = 4) metabolic response in 16 of 23 patients with complete or partial clinical response. These fi ndings were all confi rmed at 6-month scanning. PET/CT indicated refractory or persistent disease at 2 and 6 months in the remaining seven patients. Better overall survival was observed for patients with a reduction in the maximum standard uptake value of 49% or higher (both at 2 and 6 months after RIT) when compared with those with a decrease of less than 49% ( p < 0 .05). Conclusion: Early assessment of response to RIT by using PET/CT might be useful in the identifi cation of patients needing additional therapeutic strategies
Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.